企業プロフィール
CorMedix Inc. 株価・ニュース・カタリスト
- ティッカー:
- CRMD
- 取引所:
- NASDAQ
- セクター:
- Biopharma
- 所在地:
- United States
株価パフォーマンス
7.67 USD (+1.72%)
終値
最終更新: 2026年8月17日
641M USD
時価総額
株価変動の要因
As of Aug 17, 2026, CRMD closed up 1.72% at $7.67. No new same-company headline was identified in the current news window.
企業概要
Institutional Anti-Infective Company
CorMedix Therapeutics develops and commercializes products used in hospitals, dialysis clinics, infusion centers, and other institutional settings of care.
DefenCath
DefenCath is a taurolidine and heparin catheter-lock solution used to reduce catheter-related bloodstream infections in adult hemodialysis patients with central venous catheters. It is the company’s largest commercial product.
Acquired Melinta Portfolio
The Melinta acquisition added marketed anti-infectives, including REZZAYO, and expanded CorMedix’s hospital-focused commercial organization.
Late-Stage Expansion Programs
CorMedix is developing REZZAYO for prophylaxis of invasive fungal disease after allogeneic stem-cell transplantation and DefenCath for patients receiving total parenteral nutrition.
今後のカタリスト
- Submission of an sNDA for REZZAYO prophylaxis in the third quarter of 2026.
- Potential FDA action on the REZZAYO sNDA in the first half of 2027.
最近のニュース
- 01
- 02
- 03
- 04
- 05
類似銘柄
事業成熟度、治療領域、カタリスト傾向が近い同業銘柄です。